SNSESensei Biotherapeutics, Inc.

Nasdaq senseibio.com


$ 0.58 $ 0.04 (6.56 %)    

Monday, 05-Aug-2024 09:49:29 EDT
QQQ $ 435.13 $ -10.45 (-2.35 %)
DIA $ 387.79 $ -4.73 (-1.21 %)
SPY $ 518.50 $ -9.29 (-1.76 %)
TLT $ 95.87 $ -0.17 (-0.18 %)
GLD $ 220.55 $ -1.46 (-0.66 %)
$ 0.65
$ 0.60 x 100
-- x --
-- - --
$ 0.51 - $ 1.94
29,304
na
16.32M
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-29-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-29-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-15-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-sensei-biotherapeutics-maintains-4-price-target

HC Wainwright & Co. analyst Edward White reiterates Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy and maintains $4 pri...

 citigroup-reinstates-buy-on-sensei-biotherapeutics-announces-4-price-target

Citigroup analyst Samantha Semenkow reinstates Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy and announces $4 price target.

 hc-wainwright--co-reiterates-buy-on-sensei-biotherapeutics-maintains-4-price-target

HC Wainwright & Co. analyst Edward White reiterates Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy and maintains $4 pri...

 stephens--co-reiterates-overweight-on-sensei-biotherapeutics-maintains-5-price-target

Stephens & Co. analyst Sudan Loganathan reiterates Sensei Biotherapeutics (NASDAQ:SNSE) with a Overweight and maintains ...

 stephens--co-initiates-coverage-on-sensei-biotherapeutics-with-overweight-rating-announces-price-target-of-5

Stephens & Co. analyst Sudan Loganathan initiates coverage on Sensei Biotherapeutics (NASDAQ:SNSE) with a Overweight rat...

 sensei-biotherapeutics-to-present-topline-clinical-data-from-the-sns-101-phase-i-dose-escalation-study-at-the-2024-asco-annual-meeting

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development o...

 sensei-biotherapeutics-announces-nature-communications-publication-describing-mechanism-of-action-of-sns-101-selectively-targeting-the-active-form-of-vista-within-the-tumor-microenvironment

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION